Guidelines for Anticoagulation Therapy for Secondary Prevention After Deep Vein Thrombosis
Introduction
June 2011
Welcome to Mayo Medical Laboratories' Hot Topics. These presentations provide short discussions of current topics and may be helpful to you in your practice.
Our presenter for this program is Robert D. McBane, MD, Consultant, Division of Cardiovascular Diseases and Mayo Special Coagulation Laboratories and Coagulation Clinical Centers, Professor of Medicine, Mayo Clinic College of Medicine at Mayo Clinic in Rochester, Minnesota. Dr. McBane will describe laboratory testing for thrombophilia and discuss current guidelines for anticoagulation therapy following deep vein thrombosis and pulmonary embolism.
Introduction |
Jump to section:
- Independent Risk Factors for Venous Thromboembolism1
- Thrombophilia Testing
- ACCP Treatment Duration Guidelines2
- Aggressive Thrombophilia2
- Case
- Case
- Recurrence Rate
- ACCP Treatment Duration Guidelines3
- D-Dimer Levels and Risk of Recurrent Venous Thromboembolism4
- PROLONG: D-Dimer Testing to Determine Duration of Anticoagulation5
- PROLONG: D-Dimer Testing to Determine Duration of Anticoagulation5
- Idiopathic VTE
- Residual Vein Thrombosis (RVT) to Assess Optimal Management of DVT: DACUS Study6
- Residual Vein Thrombosis (RVT) to Determine Duration of Anticoagulation6
- Recurrent VTE by RVT at 3 Months: DACUS Study6
- Non-compressed vs. Compressed
- Idiopathic DVT: Take Home Point
- Case (revisited)
- Case (revisited)
- Mortality Risk
- Cumulative Recurrence of DVT vs PE After Incident DVT
- Cumulative Recurrence of DVT vs PE After Incident PE
- Independent Predictors of Death within 7 Days of Venous Thromboembolism Recurrence
- Idiopathic PE – Take Home Points
- References
- Clinical and Laboratory Update in Thrombosis and Anticoagulation
- Questions?
External
link
PDF
document
Excel
document
Word
document